A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/095 (2006.01)
Patent
CA 2566509
The established dogma for meningococcus is thus that immunisation against serogroups A, C, W135 and Y shall be based on the four different capsular saccharides, and that immunisation against serogroup B shall not be based on the capsular saccharide. In contrast, the invention uses polypeptide antigens and/or OMVs to immunise against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W 135 and Y.
Selon la théorie établie concernant le méningocoque, l'immunisation contre les sérogroupes A, C, W135 et Y doit s'appuyer sur les quatre différents saccharides capsulaires, et l'immunisation contre le sérogroupe B ne doit pas s'appuyer sur le saccharide capsulaire. En revanche, l'invention concerne l'utilisation d'antigènes polypeptidiques et/ou des OMV par rapport à l'immunisation contre les sérogroupes A, C, W135 et Y (notamment contre le sérogroupe Y). Les polypeptides du sérogroupe B peuvent assurer cette protection, ce qui permet d'utiliser un vaccin à base de polypeptides simples pour la protection contre tous les sérogroupes A, C, W135 et Y.
Contorni Mario
Giuliani Marzia
Pizza Mariagrazia
Borden Ladner Gervais Llp
Chiron Srl
Novartis Vaccines And Diagnostics S.r.l.
LandOfFree
Immunising against meningococcal serogroup y using proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunising against meningococcal serogroup y using proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunising against meningococcal serogroup y using proteins will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2001740